In 2012, Indiana civic and corporate leaders called for building a non-profit research institute that could attract world class research talent to Indiana to enable discovery science and innovation, working in collaboration with academic and industry researchers.
In 2018, the IBRI significantly expanded its research capabilities, broadening its collaborations with life sciences companies and research universities. The IBRI Diabetes Center (IDC), which will eventually have new researchers and scientific teams from the IBRI-based Lilly Diabetes Center of Excellence (LDCE), a collaboration involving Eli Lilly and Company, Indiana University (IU) School of Medicine and the IBRI, was established. And, the newest research area, the Pharmaceutical Biotechnology Center (PBC), which will initially focus on the development of therapeutic antibodies and vaccines, was estblished. Employment grew to 35.